Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer

KRAS is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different KRAS mutations may represent a unique biologic context with different prognostic and therapeutic impact. We sought to characterize genomic landscape...

Descripción completa

Detalles Bibliográficos
Autores principales: Judd, Julia, Abdel Karim, Nagla, Khan, Hina, Naqash, Abdul Rafeh, Baca, Yasmine, Xiu, Joanne, VanderWalde, Ari M., Mamdani, Hirva, Raez, Luis E., Nagasaka, Misako, Pai, Sachin Gopalkrishna, Socinski, Mark A., Nieva, Jorge J., Kim, Chul, Wozniak, Antoinette J., Ikpeazu, Chukwuemeka, de Lima Lopes, Gilberto, Spira, Alexander I., Korn, W. Michael, Kim, Edward S., Liu, Stephen V., Borghaei, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662933/
https://www.ncbi.nlm.nih.gov/pubmed/34518295
http://dx.doi.org/10.1158/1535-7163.MCT-21-0201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662933/
https://www.ncbi.nlm.nih.gov/pubmed/34518295
http://dx.doi.org/10.1158/1535-7163.MCT-21-0201

Ejemplares similares